Stock research
Healthcare · Biotechnology
Basis: Adjusted daily closes.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.
Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies